

John N Galgiani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6167434/publications.pdf>

Version: 2024-02-01

143
papers

8,661
citations

53660

45
h-index

46693

89
g-index

147
all docs

147
docs citations

147
times ranked

4581
citing authors

#	ARTICLE	IF	CITATIONS
1	Coccidioidomycosis. <i>Clinical Infectious Diseases</i> , 2005, 41, 1217-1223.	2.9	602
2	NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis. <i>American Journal of Medicine</i> , 1994, 97, 135-144.	0.6	474
3	2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis. <i>Clinical Infectious Diseases</i> , 2016, 63, e112-e146.	2.9	399
4	An insight into the antifungal pipeline: selected new molecules and beyond. <i>Nature Reviews Drug Discovery</i> , 2010, 9, 719-727.	21.5	360
5	The Role of Understaffing in Central Venous Catheter-Associated Bloodstream Infection. <i>Infection Control and Hospital Epidemiology</i> , 1996, 17, 150-158.	1.0	312
6	Comparative genomic analyses of the human fungal pathogens <i>Coccidioides</i> and their relatives. <i>Genome Research</i> , 2009, 19, 1722-1731.	2.4	295
7	Comparison of Oral Fluconazole and Itraconazole for Progressive, Nonmeningeal Coccidioidomycosis. <i>Annals of Internal Medicine</i> , 2000, 133, 676.	2.0	253
8	The Role of Understaffing in Central Venous Catheter-Associated Bloodstream Infections. <i>Infection Control and Hospital Epidemiology</i> , 1996, 17, 150-158.	1.0	244
9	Coccidioidomycosis as a Common Cause of Community-acquired Pneumonia. <i>Emerging Infectious Diseases</i> , 2006, 12, 958-962.	2.0	234
10	Recent Advances in Our Understanding of the Environmental, Epidemiological, Immunological, and Clinical Dimensions of Coccidioidomycosis. <i>Clinical Microbiology Reviews</i> , 2013, 26, 505-525.	5.7	223
11	Signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations and disseminated coccidioidomycosis and histoplasmosis. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 131, 1624-1634.e17.	1.5	222
12	Fluconazole Therapy for Coccidioidal Meningitis. <i>Annals of Internal Medicine</i> , 1993, 119, 28.	2.0	188
13	Coccidioidomycosis during Human Immunodeficiency Virus Infection. <i>Medicine (United States)</i> , 1990, 69, 384-391.	0.4	183
14	Itraconazole treatment of coccidioidomycosis. <i>American Journal of Medicine</i> , 1990, 89, 282-290.	0.6	170
15	Coccidioidomycosis during human immunodeficiency virus infection: results of a prospective study in a coccidioidal endemic area. <i>American Journal of Medicine</i> , 1993, 94, 235-240.	0.6	169
16	Population genomic sequencing of <i>Coccidioides</i> fungi reveals recent hybridization and transposon control. <i>Genome Research</i> , 2010, 20, 938-946.	2.4	166
17	Antimicrobial Susceptibility Testing of Yeasts: a Turbidimetric Technique Independent of Inoculum Size. <i>Antimicrobial Agents and Chemotherapy</i> , 1976, 10, 721-726.	1.4	162
18	Visceral fungal infections due to <i>petriellidium boydii</i> (<i>allescheria boydii</i>). <i>American Journal of Medicine</i> , 1976, 61, 632-640.	0.6	161

#	ARTICLE	IF	CITATIONS
19	Coccidioidomycosis: A Regional Disease of National Importance: Rethinking Approaches for Control. <i>Annals of Internal Medicine</i> , 1999, 130, 293.	2.0	155
20	Gynecomastia with Ketoconazole. <i>Antimicrobial Agents and Chemotherapy</i> , 1981, 19, 1073-1074.	1.4	151
21	Fluconazole in the treatment of chronic pulmonary and nonmeningeal disseminated coccidioidomycosis. <i>American Journal of Medicine</i> , 1995, 98, 249-256.	0.6	131
22	An Epidemic of Coccidioidomycosis in Arizona Associated with Climatic Changes, 1998â€“2001. <i>Journal of Infectious Diseases</i> , 2005, 191, 1981-1987.	1.9	124
23	Safety, Tolerance, and Efficacy of Posaconazole Therapy in Patients with Nonmeningeal Disseminated or Chronic Pulmonary Coccidioidomycosis. <i>Clinical Infectious Diseases</i> , 2007, 45, 562-568.	2.9	110
24	Refractory Disseminated Coccidioidomycosis and Mycobacteriosis in Interferon-Î³ Receptor 1 Deficiency. <i>Clinical Infectious Diseases</i> , 2009, 49, e62-e65.	2.9	109
25	Fluconazole, a New Antifungal Agent. <i>Annals of Internal Medicine</i> , 1990, 113, 177.	2.0	107
26	The Public Health Impact of Coccidioidomycosis in Arizona and California. <i>International Journal of Environmental Research and Public Health</i> , 2011, 8, 1150-1173.	1.2	105
27	Risk Factors for Disseminated Coccidioidomycosis, United States. <i>Emerging Infectious Diseases</i> , 2017, 23, .	2.0	100
28	Ketoconazole therapy of progressive coccidioidomycosis. <i>American Journal of Medicine</i> , 1988, 84, 603-610.	0.6	96
29	Interleukin-12 Receptor Î1 Deficiency Predisposing to Disseminated Coccidioidomycosis. <i>Clinical Infectious Diseases</i> , 2011, 52, e99-e102.	2.9	87
30	Executive Summary: 2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis. <i>Clinical Infectious Diseases</i> , 2016, 63, 717-722.	2.9	87
31	Pharmacokinetics of Nikkomycin Z after Single Rising Oral Doses. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 2517-2521.	1.4	75
32	Factors and Outcomes Associated with the Decision to Treat Primary Pulmonary Coccidioidomycosis. <i>Clinical Infectious Diseases</i> , 2009, 48, 172-178.	2.9	73
33	Turbidimetric Studies of Growth Inhibition of Yeasts with Three Drugs: Inquiry into Inoculum-Dependent Susceptibility Testing, Time of Onset of Drug Effect, and Implications for Current and Newer Methods. <i>Antimicrobial Agents and Chemotherapy</i> , 1978, 13, 249-254.	1.4	71
34	Regional dust storm modeling for health services: The case of valley fever. <i>Aeolian Research</i> , 2014, 14, 53-73.	1.1	71
35	Evaluation of the Proline-Rich Antigen of <i>Coccidioides immitis</i> as a Vaccine Candidate in Mice. <i>Infection and Immunity</i> , 1998, 66, 3519-3522.	1.0	65
36	Coccidioidomycosis during Pregnancy. <i>Chest</i> , 1988, 94, 376-379.	0.4	62

#	ARTICLE	IF	CITATIONS
37	Coccidioidomycosis among Visitors to a <i>Coccidioides immitis</i> -Endemic Area: An Outbreak in a Military Reserve Unit. <i>Journal of Infectious Diseases</i> , 1995, 171, 1672-1675.	1.9	56
38	Improved protection of mice against lethal respiratory infection with <i>Coccidioides posadasii</i> using two recombinant antigens expressed as a single protein. <i>Vaccine</i> , 2006, 24, 5904-5911.	1.7	56
39	Resistance to <i>Coccidioides immitis</i> in Mice after Immunization with Recombinant Protein or a DNA Vaccine of a Proline-Rich Antigen. <i>Infection and Immunity</i> , 1999, 67, 2935-2940.	1.0	54
40	Modeling Nikkomycin Z Dosing and Pharmacology in Murine Pulmonary Coccidioidomycosis Preparatory to Phase 2 Clinical Trials. <i>Journal of Infectious Diseases</i> , 2014, 209, 1949-1954.	1.9	53
41	Protection of Mice against <i>Coccidioides immitis</i> Intranasal Infection by Vaccination with Recombinant Antigen 2/PRA. <i>Infection and Immunity</i> , 2002, 70, 3287-3289.	1.0	52
42	<i>Coccidioides posadasii</i> contains single chitin synthase genes corresponding to classes I to VII. <i>Fungal Genetics and Biology</i> , 2006, 43, 775-788.	0.9	51
43	Cloning and Sequence Analysis of the cDNA for a Protein from <i>Coccidioides immitis</i> with Immunogenic Potential. <i>Biochemical and Biophysical Research Communications</i> , 1996, 218, 485-489.	1.0	48
44	Vaccine-Induced Cellular Immune Responses Differ from Innate Responses in Susceptible and Resistant Strains of Mice Infected with <i>Coccidioides posadasii</i> . <i>Infection and Immunity</i> , 2008, 76, 5553-5564.	1.0	47
45	Physical Characterization of the α Immunosignaling Effect. <i>Molecular and Cellular Proteomics</i> , 2012, 11, M111.011593.	2.5	47
46	Management of coccidioidomycosis in patients receiving biologic response modifiers or disease-modifying antirheumatic drugs. <i>Arthritis Care and Research</i> , 2012, 64, 1903-1909.	1.5	47
47	A <i>Coccidioides posadasii</i> CPS1 Deletion Mutant Is Avirulent and Protects Mice from Lethal Infection. <i>Infection and Immunity</i> , 2016, 84, 3007-3016.	1.0	47
48	Ketoconazole treatment of nonprimary coccidioidomycosis. <i>American Journal of Medicine</i> , 1982, 72, 681-687.	0.6	46
49	Evaluation of VT-1161 for Treatment of Coccidioidomycosis in Murine Infection Models. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 7249-7254.	1.4	46
50	Protein Expression Profiling of <i>Coccidioides posadasii</i> by Two-Dimensional Differential In-Gel Electrophoresis and Evaluation of a Newly Recognized Peroxisomal Matrix Protein as a Recombinant Vaccine Candidate. <i>Infection and Immunity</i> , 2006, 74, 1865-1872.	1.0	44
51	Legionnaires™ Disease Following Cardiac Transplantation. <i>Chest</i> , 1981, 79, 669-671.	0.4	43
52	The Return of Delayed-Type Hypersensitivity Skin Testing for Coccidioidomycosis. <i>Clinical Infectious Diseases</i> , 2015, 61, 787-791.	2.9	43
53	<i>Bacteroides fragilis</i> endocarditis, bacteremia and other infections treated with oral or intravenous metronidazole. <i>American Journal of Medicine</i> , 1978, 65, 284-289.	0.6	41
54	MARKERS OF COCCIDIOIDOMYCOSIS BEFORE CARDIAC OR RENAL TRANSPLANTATION AND THE RISK OF RECURRENT INFECTION. <i>Transplantation</i> , 1993, 55, 1422-1424.	0.5	38

#	ARTICLE	IF	CITATIONS
55	<i>Coccidioides posadasii</i> Contains a Single 1,3- β -Glucan Synthase Gene That Appears To Be Essential for Growth. <i>Eukaryotic Cell</i> , 2005, 4, 111-120.	3.4	38
56	The Rise of <i>Coccidioides</i> : Forces Against the Dust Devil Unleashed. <i>Frontiers in Immunology</i> , 2019, 10, 2188.	2.2	37
57	Glucan-Chitin Particles Enhance Th17 Response and Improve Protective Efficacy of a Multivalent Antigen (rCpa1) against Pulmonary <i>Coccidioides posadasii</i> Infection. <i>Infection and Immunity</i> , 2018, 86, .	1.0	36
58	Antigenemia in Primary <i>Coccidioidomycosis</i> *. <i>American Journal of Tropical Medicine and Hygiene</i> , 1984, 33, 645-649.	0.6	36
59	Efficacy of Nikkomycin Z for respiratory <i>coccidioidomycosis</i> in naturally infected dogs. <i>Medical Mycology</i> , 2013, 51, 747-754.	0.3	35
60	Human Polymorphonuclear-Leukocyte Inhibition of Incorporation of Chitin Precursors into Mycelia of <i>Coccidioides immitis</i> . <i>Journal of Infectious Diseases</i> , 1984, 149, 404-412.	1.9	34
61	Extraction of serologic and delayed hypersensitivity antigens from spherules of <i>Coccidioides immitis</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 1988, 11, 65-80.	0.8	33
62	Amphotericin B and imidazole therapy for coccidioidal meningitis in children. <i>Pediatric Infectious Disease Journal</i> , 1983, 2, 216-221.	1.1	32
63	Spherules Derived from <i>Coccidioides posadasii</i> Promote Human Dendritic Cell Maturation and Activation. <i>Infection and Immunity</i> , 2006, 74, 2415-2422.	1.0	32
64	Characterizing in vitro spherule morphogenesis of multiple strains of both species of <i>Coccidioides</i> . <i>Medical Mycology</i> , 2019, 57, 478-488.	0.3	32
65	Cavitary <i>Coccidioidomycosis</i> With Fungus Ball Formation. <i>Chest</i> , 1994, 105, 412-416.	0.4	31
66	Evaluation of 80% inhibition standards for the determination of fluconazole minimum inhibitory concentrations in three laboratories. <i>Diagnostic Microbiology and Infectious Disease</i> , 1994, 20, 81-86.	0.8	28
67	Population Structure and Genetic Diversity among Isolates of <i>Coccidioides posadasii</i> in Venezuela and Surrounding Regions. <i>MBio</i> , 2019, 10, .	1.8	28
68	Localization within a Proline-Rich Antigen (Ag2/PRA) of Protective Antigenicity against Infection with <i>Coccidioides immitis</i> in Mice. <i>Infection and Immunity</i> , 2002, 70, 3330-3335.	1.0	27
69	<i>Coccidioidomycosis</i> : Changing Perceptions and Creating Opportunities for Its Control. <i>Annals of the New York Academy of Sciences</i> , 2007, 1111, 1-18.	1.8	27
70	Comparison of a Novel Rapid Lateral Flow Assay to Enzyme Immunoassay Results for Early Diagnosis of <i>Coccidioidomycosis</i> . <i>Clinical Infectious Diseases</i> , 2021, 73, e2746-e2753.	2.9	27
71	Paracoccidioidomycosis (South American Blastomycosis): Treatment with Miconazole *. <i>American Journal of Tropical Medicine and Hygiene</i> , 1978, 27, 801-807.	0.6	26
72	Ketoconazole in the Treatment of <i>Coccidioidomycosis</i> . <i>Drugs</i> , 1983, 26, 355-363.	4.9	24

#	ARTICLE	IF	CITATIONS
73	Ketoconazole Treatment of Coccidioidal Meningitis. <i>Annals of the New York Academy of Sciences</i> , 1988, 544, 488-496.	1.8	24
74	Coccidioidal Peritonitis Associated With Continuous Ambulatory Peritoneal Dialysis. <i>American Journal of Kidney Diseases</i> , 1988, 11, 512-514.	2.1	24
75	Safety, Antigenicity, and Efficacy of a Recombinant Coccidioidomycosis Vaccine in Cynomolgus Macaques (<i>Macaca fascicularis</i>). <i>Annals of the New York Academy of Sciences</i> , 2007, 1111, 290-300.	1.8	23
76	Viable spores of <i>Coccidioides posadasii</i> cps1 are required for vaccination and provide long lasting immunity. <i>Vaccine</i> , 2018, 36, 3375-3380.	1.7	22
77	Delays in Coccidioidomycosis Diagnosis and Associated Healthcare Utilization, Tucson, Arizona, USA. <i>Emerging Infectious Diseases</i> , 2019, 25, 1745-1747.	2.0	22
78	Application of Immunosignatures for Diagnosis of Valley Fever. <i>Vaccine Journal</i> , 2014, 21, 1169-1177.	3.2	21
79	Efficacy of Ambruticin Analogs in a Murine Model of Coccidioidomycosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 3467-3469.	1.4	20
80	Treatment for Early, Uncomplicated Coccidioidomycosis: What Is Success?. <i>Clinical Infectious Diseases</i> , 2020, 70, 2008-2012.	2.9	20
81	Natural History of Disseminated Coccidioidomycosis: Examination of the Veterans Affairs' Armed Forces Database. <i>Clinical Infectious Diseases</i> , 2021, 73, e3814-e3819.	2.9	20
82	Early Events in Coccidioidomycosis. <i>Clinical Microbiology Reviews</i> , 2019, 33, .	5.7	19
83	A Chronic Murine Disease Model of Coccidioidomycosis Using <i>Coccidioides posadasii</i> , Strain 1038. <i>Journal of Infectious Diseases</i> , 2021, 223, 166-173.	1.9	17
84	Persistent Coccidioidal Seropositivity Without Clinical Evidence of Active Coccidioidomycosis in Patients Infected with Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 1995, 20, 1281-1285.	2.9	16
85	Analysis of Autoantibodies to T-Cell Receptors among HIV-Infected Individuals: Epitope Analysis and Time Course. <i>Clinical Immunology and Immunopathology</i> , 1997, 82, 174-189.	2.1	16
86	Vaccines to Prevent Systemic Mycoses: Holy Grails Meet Translational Realities. <i>Journal of Infectious Diseases</i> , 2008, 197, 938-940.	1.9	16
87	Mouse models for the study of fungal pneumonia. <i>Virulence</i> , 2012, 3, 329-338.	1.8	16
88	A paradigm for the evaluation and management of spinal coccidioidomycosis. , 2015, 6, 107.		15
89	Development of Dermal Hypersensitivity to Coccidioidal Antigens Associated with Repeated Skin Testing ¹⁻³ . <i>The American Review of Respiratory Disease</i> , 1986, 134, 1045-1047.	2.9	14
90	Interaction of human peripheral blood mononuclear cells with <i>Coccidioides immitis</i> arthroconidia. <i>Cellular Immunology</i> , 1991, 133, 253-262.	1.4	14

#	ARTICLE	IF	CITATIONS
91	ŕ”cps1 vaccine protects dogs against experimentally induced coccidioidomycosis. <i>Vaccine</i> , 2021, 39, 6894-6901.	1.7	14
92	Coccidioidomycosis among Scholarship Athletes and Other College Students, Arizona, USA1. <i>Emerging Infectious Diseases</i> , 2010, 16, 321-323.	2.0	13
93	Differential Thermotolerance Adaptation between Species of <i>Coccidioides</i> . <i>Journal of Fungi (Basel.)</i> Tj ETQq1 1 0.784314 rgBT /Overlo	1.5	13
94	Clinical and Economic Burden of Valley Fever in Arizona: An Incidence-Based Cost-of-Illness Analysis. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa623.	0.4	13
95	Delays in Coccidioidomycosis Diagnosis and Relationship to Healthcare Utilization, Phoenix, Arizona, USA¹. <i>Emerging Infectious Diseases</i> , 2019, 25, 1742-1744.	2.0	13
96	Detecting Serum Antibodies to a Purified Recombinant Prolineâ€Rich Antigen of <i>Coccidioides immitis</i> in Patients with Coccidioidomycosis. <i>Clinical Infectious Diseases</i> , 1998, 27, 1475-1478.	2.9	12
97	Demonstration of <i>N</i>, <i>N</i>-Dimethyldithiocarbamate as a Copper-Dependent Antibiotic against Multiple Upper Respiratory Tract Pathogens. <i>Microbiology Spectrum</i> , 2021, 9, e0077821.	1.2	12
98	Mannose-Binding Lectin Serum Levels are Low in Persons with Clinically Active Coccidioidomycosis. <i>Mycopathologia</i> , 2009, 167, 173-180.	1.3	11
99	Top Questions in the Diagnosis and Treatment of Coccidioidomycosis. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx197.	0.4	11
100	Coccidioid Meningitis in New York Traced to Texas by Fungal Genomic Analysis. <i>Clinical Infectious Diseases</i> , 2019, 69, 1060-1062.	2.9	11
101	Clinician Practice Patterns That Result in the Diagnosis of Coccidioidomycosis Before or During Hospitalization. <i>Clinical Infectious Diseases</i> , 2020, 73, e1587-e1593.	2.9	11
102	Differences in Oxidant Release by Human Polymorphonuclear Leukocytes Produced by Stimulation with Different Phases of <i>Coccidioides immitis</i> . <i>Journal of Infectious Diseases</i> , 1995, 172, 199-203.	1.9	10
103	Effect of Geography on the Analysis of Coccidioidomycosis-Associated Deaths, United States. <i>Emerging Infectious Diseases</i> , 2016, 22, 1821-1823.	2.0	10
104	Coccidioidomycosis: The Initial Pulmonary Infection and Beyond. <i>Seminars in Respiratory and Critical Care Medicine</i> , 1997, 18, 235-247.	0.8	9
105	Mouse Model of a Human STAT4 Point Mutation That Predisposes to Disseminated Coccidiomycosis. <i>ImmunoHorizons</i> , 2022, 6, 130-143.	0.8	9
106	The WOPR family protein Ryp1 is a key regulator of gene expression, development, and virulence in the thermally dimorphic fungal pathogen <i>Coccidioides posadasii</i> . <i>PLoS Pathogens</i> , 2022, 18, e1009832.	2.1	9
107	The Application of Proteomic Techniques to Fungal Protein Identification and Quantification. <i>Annals of the New York Academy of Sciences</i> , 2007, 1111, 133-146.	1.8	8
108	A quantitative enzyme-linked immunoassay (ELISA) to approximate complement-fixing antibody titers in serum from patients with coccidioidomycosis. <i>Diagnostic Microbiology and Infectious Disease</i> , 2021, 99, 115198.	0.8	8

#	ARTICLE	IF	CITATIONS
109	Controversies in the Management of Central Nervous System Coccidioidomycosis. <i>Clinical Infectious Diseases</i> , 2022, 75, 555-559.	2.9	8
110	Nuclear Labeling of <i>Coccidioides posadasii</i> with Green Fluorescent Protein. <i>Annals of the New York Academy of Sciences</i> , 2007, 1111, 198-207.	1.8	7
111	Delays in Coccidioidomycosis Diagnosis and Relationship to Healthcare Utilization, Arizona, USA1. <i>Emerging Infectious Diseases</i> , 2019, 25, 1742-1744.	2.0	7
112	Susceptibility of <i>Candida albicans</i> to flucytosine when tested in different formulations of yeast nitrogen base broth. <i>Diagnostic Microbiology and Infectious Disease</i> , 1986, 5, 273-276.	0.8	6
113	Comparative analysis of three antifungal susceptibility test methods against prospectively collected <i>Candida</i> species. <i>Diagnostic Microbiology and Infectious Disease</i> , 1994, 18, 89-94.	0.8	6
114	Delays in Coccidioidomycosis Diagnosis and Associated Healthcare Utilization, Tucson, Arizona, USA. <i>Emerging Infectious Diseases</i> , 2019, 25, 1745-1747.	2.0	6
115	How does genetics influence valley fever? research underway now to answer this question. <i>Southwest Journal of Pulmonary & Critical Care</i> , 0, , 230-237.	0.0	5
116	42. Common Population Variants Cause Susceptibility to Disseminated Coccidioidomycosis. <i>Open Forum Infectious Diseases</i> , 2020, 7, S22-S23.	0.4	5
117	Vaccine Protection of Mice With Primary Immunodeficiencies Against Disseminated Coccidioidomycosis. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 790488.	1.8	5
118	Studies of the effects of spherulin from <i>Coccidioides immitis</i> on human polymorpho-nuclear leukocytes. <i>Mycopathologia</i> , 1985, 90, 107-111.	1.3	4
119	Molecular approaches to the study of <i>Coccidioides immitis</i> . <i>International Journal of Medical Microbiology</i> , 2002, 292, 373-380.	1.5	4
120	Approach to Management of Coccidioidomycosis in Patients Receiving Inhibitors of Tumor Necrosis Factor- α . <i>Infectious Diseases in Clinical Practice</i> , 2017, 25, 184-192.	0.1	4
121	Coccidioidomycosis (<i>Coccidioides</i> Species). , 2015, , 2974-2984.e3.		4
122	A randomized, double-blind, placebo-controlled clinical trial of fluconazole as early empiric treatment of coccidioidomycosis pneumonia (Valley Fever) in adults presenting with community-acquired pneumonia in endemic areas (FLEET-Valley Fever). <i>Contemporary Clinical Trials Communications</i> , 2021, 24, 100851.	0.5	4
123	Coccidioidomycosis. <i>Chest</i> , 1982, 81, 488-492.	0.4	3
124	2888. STAT4 Mutation in Three Generations with Disseminated Coccidioidomycosis (DCM) also Exhibits Increased Susceptibility to Coccidioidal Infection in Transfected Mice. <i>Open Forum Infectious Diseases</i> , 2019, 6, S77-S78.	0.4	3
125	FDA Public Workshop Summary "Coccidioidomycosis (Valley Fever): Considerations for Development of Antifungal Drugs. <i>Clinical Infectious Diseases</i> , 2021, , .	2.9	3
126	TNF α Blockade Inhibits Both Initial and Continued Control of Pulmonary <i>Coccidioides</i> . <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 796114.	1.8	3

#	ARTICLE	IF	CITATIONS
127	Cross-Sectional Study of Clinical Predictors of Coccidioidomycosis, Arizona, USA. <i>Emerging Infectious Diseases</i> , 2022, 28, 1091-1100.	2.0	3
128	Editorial Commentary: Elements of Style in Managing Coccidioidomycosis. <i>Clinical Infectious Diseases</i> , 2013, 56, 1586-1588.	2.9	2
129	1732. A Canine Target Species Challenge Model to Evaluate Efficacy of a Coccidioidomycosis Vaccine. <i>Open Forum Infectious Diseases</i> , 2019, 6, S634-S635.	0.4	2
130	Common mistakes in managing pulmonary coccidioidomycosis. <i>Southwest Journal of Pulmonary & Critical Care</i> , 2015, 10, 238-249.	0.0	2
131	Contribution of Biologic Response Modifiers to the Risk of Coccidioidomycosis Severity. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac032.	0.4	2
132	Integrating Automated Biomedical Lexicon Creation for Valley Fever Diagnosis. , 2021, , .		2
133	The <i>Cryptococcus neoformans</i> GeneDHA1 Encodes an Antigen That Elicits a Delayed-Type Hypersensitivity Reaction in Immune Mice. <i>Infection and Immunity</i> , 2000, 68, 6196-6201.	1.0	2
134	386. A Reexamination of Disseminated Coccidioidomycosis: The Natural History in the Pre-Antifungal Era. <i>Open Forum Infectious Diseases</i> , 2018, 5, S149-S150.	0.4	1
135	Tip of the iceberg: 18F-FDG PET/CT diagnoses extensively disseminated coccidioidomycosis with cutaneous lesions. <i>Southwest Journal of Pulmonary & Critical Care</i> , 2017, 15, 28-31.	0.0	1
136	Pertussis vaccine: An unnecessary renewal of anti-vaccine sentiment. <i>Infectious Diseases Newsletter (New York, N Y)</i> , 1982, 1, 69-71.	0.2	0
137	Program for the 45th coccidioidomycosis study group Tucson, Arizona, March 31, 2001. <i>Mycopathologia</i> , 2002, 154, 1-13.	1.3	0
138	Natural History of Non-CNS Disseminated Coccidioidomycosis. <i>Open Forum Infectious Diseases</i> , 2017, 4, S77-S77.	0.4	0
139	Oxygen Consumption Deficits in Patients With Residual Fatigue After Primary Coccidioidomycosis. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx136.	0.4	0
140	1718. The Natural History of Chronic Pulmonary Coccidioidomycosis in the Pre-Antifungal Era. <i>Open Forum Infectious Diseases</i> , 2019, 6, S630-S630.	0.4	0
141	2598. Macrophage Migration Inhibitory Factor May Contribute to Disseminated Coccidioidomycosis Susceptibility. <i>Open Forum Infectious Diseases</i> , 2019, 6, S903-S903.	0.4	0
142	A Pilot Study of Valley Fever Tweets. <i>Infection Control and Hospital Epidemiology</i> , 2020, 41, s101-s101.	1.0	0
143	Payer Coverage of Valley Fever Diagnostic Tests. <i>Southwest Journal of Pulmonary & Critical Care</i> , 2021, 23, 155-161.	0.0	0